Several reports revealed that afatinib, an irreversible pan‐ErbB family blocker, has potential activity against osimertinib‐resistant lung cancer because it has been proven effective against tumors with both minor and compound EGFR mutations. This evidence concerns the gene EGFR and lung carcinoma.